Cycloastragenol Delivery Systems

1. Overview & Definition

Cycloastragenol (CAG; CAS 84605-18-5) is a triterpenoid saponin aglycone and the active hydrolysis product of astragaloside IV. It has been reported to activate telomerase reverse transcriptase (TERT) through an as-yet-undefined allosteric mechanism, though the magnitude of this effect in primary human cells remains modest and context-dependent.

Despite preclinical interest, CAG presents formidable drug-delivery challenges:

• Aqueous solubility: ~0.02 mg/mL (practically insoluble in water)
• LogP: ~6.8 (highly lipophilic)
• Molecular weight: 490.72 g/mol
• Permeability: Low (BCS Class IV compound — low solubility, low permeability)

These properties mean that unformulated CAG undergoes extensive first-pass hepatic metabolism, achieves low plasma concentrations, and exhibits high inter-individual variability in absorption. Delivery technologies aim to increase the fraction of an oral dose that reaches systemic circulation in active form.

2. The Bioavailability Problem

2.1 Solubility-Limited Absorption

Under the Biopharmaceutics Classification System (BCS), CAG falls into Class IV: low solubility and low permeability. For such compounds, dissolution in gastrointestinal (GI) fluids is the rate-limiting step for absorption. The maximum thermodynamic solubility of CAG in simulated intestinal fluid (pH 6.8 phosphate buffer) is approximately 0.015 mg/mL, meaning a standard 5–10 mg oral dose cannot fully dissolve in the ~250 mL of GI fluid typically present in the fasted small intestine.

2.2 Hepatic First-Pass Metabolism

Rodent pharmacokinetic studies indicate that CAG undergoes extensive hepatic metabolism, primarily via CYP3A4-mediated oxidation and subsequent glucuronidation. In rats, oral bioavailability has been reported at <5% for unformulated CAG, with the majority of an oral dose recovered as metabolites in bile and urine within 24 hours.

2.3 P-Glycoprotein Efflux

In vitro Caco-2 cell studies suggest CAG is a substrate for P-glycoprotein (P-gp/ABCB1), an ATP-dependent efflux transporter expressed on the apical membrane of intestinal enterocytes. P-gp actively pumps absorbed CAG back into the intestinal lumen, further reducing net absorption. This efflux mechanism may explain the non-linear dose-response observed in some animal studies, where increasing the oral dose yields disproportionately small increases in plasma AUC.

Sources: Wang et al. (2013); Zhang et al. (2017). Rodent-to-human extrapolation is unreliable; these data are illustrative only.

3. Delivery Technology Categories

3.1 Cyclodextrin Complexation

Cyclodextrins (CDs) are cyclic oligosaccharides with a hydrophobic internal cavity and hydrophilic external surface. β-cyclodextrin and its derivatives (hydroxypropyl-β-cyclodextrin, HP-β-CD; sulfobutylether-β-cyclodextrin, SBE-β-CD) can encapsulate lipophilic molecules like CAG, increasing apparent aqueous solubility through inclusion complex formation.

Mechanism: The CAG molecule inserts into the CD cavity, shielding its hydrophobic scaffold from water while exposing the hydrophilic CD exterior. This increases the concentration gradient for passive diffusion across the intestinal membrane.

Evidence: Liu et al. (2019) reported that a CAG/HP-β-CD complex increased the dissolution rate of CAG by ~8-fold in simulated gastric fluid and improved oral bioavailability in rats by approximately 2.3-fold compared to unformulated CAG suspension. However, the absolute bioavailability remained low (~10%), and no human pharmacokinetic data have been published.

Limitations: CD complexation increases solubility but does not address P-gp efflux or hepatic first-pass metabolism. The molecular weight of the complex (~2,300 Da for HP-β-CD + CAG) may also limit paracellular absorption.

3.2 Liposomal and Lymphatic Delivery

Liposomes are phospholipid bilayer vesicles that can encapsulate hydrophobic compounds in their lipid core. When administered orally, liposomes may protect CAG from gastric degradation and facilitate absorption via the intestinal lymphatic system, bypassing hepatic first-pass metabolism.

Mechanism: Lipids stimulate chylomicron formation in enterocytes. If CAG partitions into chylomicron triglyceride cores, it can be absorbed into intestinal lymphatics and enter systemic circulation via the thoracic duct, avoiding portal vein transport to the liver.

Evidence: Preclinical studies of liposomal CAG in rats have shown mixed results. Chen et al. (2020) reported a 3.1-fold increase in AUC_0–24h for liposomal CAG versus free CAG, with a shift in T_max from 1.5 h to 4.2 h, consistent with lymphatic absorption. However, liposomal stability in GI fluids is a major concern; phospholipases and bile salts can disrupt liposome integrity before absorption occurs.

Limitations: No published human data. Liposomal formulations are expensive to manufacture and may have limited shelf stability. The degree of lymphatic bypass in humans is unknown and likely lower than in rodents due to species differences in intestinal lipid processing.

3.3 Bioavailability Enhancers (Natural Products)

Several natural compounds have been investigated for their ability to inhibit drug-metabolizing enzymes or efflux transporters, thereby increasing CAG bioavailability:

All data from rodent models. No human pharmacokinetic studies have been published for any CAG + enhancer combination.

Critical Caveat: While these enhancers increase CAG exposure, they also inhibit detoxification pathways that protect against drug toxicity and carcinogen activation. Chronic CYP3A4 inhibition may have unintended consequences that have not been studied in the context of CAG supplementation.

3.4 Solid Dispersion / Solubilization Complexes

Solid dispersions involve dispersing a hydrophobic drug in a hydrophilic polymer matrix (e.g., PVP, PEG, Soluplus®). Upon contact with GI fluid, the polymer matrix dissolves, releasing CAG as a supersaturated or molecularly dispersed solution that drives higher absorption rates.

Evidence: Yang et al. (2021) prepared a CAG-Soluplus® solid dispersion that achieved a 12-fold increase in dissolution rate and a 4.5-fold increase in rat oral bioavailability. However, the formulation required spray-drying equipment and showed physical instability (recrystallization) after 3 months of storage at 40°C/75% RH.

4. The Delivery Matrix Concept

Some commercial formulations propose a multi-stage "delivery matrix" that combines several technologies sequentially. While this concept is pharmacologically plausible, no peer-reviewed study has evaluated a complete multi-stage matrix in humans or animals.

The theoretical framework involves four stages:

1. Solubility Enhancement: Cyclodextrin or micellar solubilization to increase the dissolved drug concentration in the GI lumen.
2. Liposomal Encapsulation: Protection from degradation and facilitation of lymphatic transport.
3. Bioactivation: Natural enhancers (piperine, naringin) to inhibit first-pass metabolism and efflux.
4. Systemic Absorption: Enhanced permeation into enterocytes and reduced presystemic clearance.

Assessment: Each stage is supported by independent preclinical studies (as described above), but the combination has not been tested. Synergistic effects are theoretically possible but unproven. Additive effects are more likely, though the magnitude cannot be predicted from single-technology studies. Any commercial claim that a multi-stage matrix achieves bioavailability increases of 10×, 50×, or higher should be treated as marketing speculation without independent peer-reviewed validation.

5. Bioavailability Claims: Evidence vs. Marketing

The CAG supplement market is characterized by aggressive bioavailability claims that often exceed what the peer-reviewed literature supports. This section deconstructs common marketing assertions and traces them back to their (often absent) evidentiary basis.

5.1 Common Marketing Claims

5.2 The Absence of Human Pharmacokinetic Data

As of July 2026, no peer-reviewed study has measured CAG plasma concentrations in humans after oral administration of any formulation — standard or enhanced. The only human CAG trial (Harley et al., 2011, published in Rejuvenation Research) used a proprietary formulation but did not report pharmacokinetic parameters. Without human PK data, all bioavailability claims are extrapolations from rodent models, which are unreliable predictors of human absorption for BCS Class IV compounds.

6. Research Gaps & Limitations

The evidence base for CAG delivery systems has several critical gaps that limit clinical translation:

6.1 No Human Pharmacokinetic Studies

Despite over a decade of commercial availability, no published study has characterized CAG absorption, distribution, metabolism, or excretion (ADME) in humans. This is the single most important gap in the field. Without human PK data, dosing recommendations are empirical rather than evidence-based.

6.2 No Standardized Analytical Assay

Different research groups use different LC-MS/MS methods with varying sensitivity, specificity, and internal standards. There is no certified reference standard for CAG in plasma, and inter-laboratory validation is absent. This makes cross-study comparison difficult and introduces uncertainty into bioavailability calculations.

6.3 No Head-to-Head Comparative Trials

No randomized controlled trial has compared two or more CAG delivery technologies in the same experimental model. All reported bioavailability enhancements are relative to unformulated CAG suspension, not to competing enhanced formulations. This means consumers and clinicians have no objective basis for comparing products.

6.4 Cancer Risk Unknown

Telomerase activation in somatic cells is a hallmark of cancer. While CAG's telomerase-activating effects are modest in primary cells, the long-term safety of chronically elevating telomerase activity — particularly with enhanced-delivery formulations that achieve higher systemic exposure — has not been studied in carcinogenesis models. This safety gap is especially concerning given that delivery technologies may increase CAG exposure by 2–4× or more.

6.5 Species Extrapolation Uncertainty

All delivery-system studies have been conducted in rodents. Rats and mice differ from humans in GI pH profiles, bile salt composition, intestinal transit time, CYP expression, and lymphatic anatomy. Bioavailability in rodents is a poor predictor of human bioavailability for lipophilic, P-gp substrates. The rodent data should be treated as hypothesis-generating, not predictive.

7. Summary Comparison Table

All bioavailability gains are relative to unformulated CAG suspension in the same study. No cross-study or cross-technology comparisons have been published. Evidence level reflects peer-reviewed publication status, not clinical validation.

8. References

1. Harley CB, Liu W, Blasco MA, et al. A natural product telomerase activator as part of a health maintenance program: metabolic and cardiovascular response. Rejuvenation Research. 2011;14(1):45-56. doi:10.1089/rej.2010.1080
2. Wang Y, Ma R, Liu F. Pharmacokinetics and tissue distribution of cycloastragenol in rats determined by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. 2013;932:37-43. doi:10.1016/j.jchromb.2013.05.024
3. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer Methods and Programs in Biomedicine. 2010;99(3):306-314. doi:10.1016/j.cmpb.2010.01.007 [Methodological reference for PK calculations]
4. Liu Y, Zhang Y, Zhang J, et al. Enhancement of oral bioavailability of cycloastragenol by hydroxypropyl-β-cyclodextrin complexation: in vitro and in vivo evaluation. Drug Development and Industrial Pharmacy. 2019;45(8):1289-1297. doi:10.1080/03639045.2019.1601245
5. Chen X, Zhang Y, Wang L, et al. Enhanced oral bioavailability of cycloastragenol via liposomal formulation: preparation, in vitro characterization, and in vivo evaluation. International Journal of Nanomedicine. 2020;15:4521-4533. doi:10.2147/IJN.S253891
6. Li X, Wang J, Chen S, et al. Piperine enhances the bioavailability of cycloastragenol in rats by inhibiting CYP3A4 and P-glycoprotein. Fitoterapia. 2018;129:148-155. doi:10.1016/j.fitote.2018.07.005
7. Wang J, Li X, Chen S, et al. Naringin improves the oral bioavailability of cycloastragenol in rats through inhibition of intestinal CYP3A4 and modulation of gut microbiota. European Journal of Drug Metabolism and Pharmacokinetics. 2019;44(5):621-630. doi:10.1007/s13318-019-00552-3
8. Yang L, Jiang Y, Zhang Y, et al. Soluplus®-based solid dispersion of cycloastragenol: preparation, characterization, and in vivo evaluation. Asian Journal of Pharmaceutical Sciences. 2021;16(4):512-523. doi:10.1016/j.ajps.2020.07.004
9. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. 1995;12(3):413-420. doi:10.1023/A:1016212804288 [BCS framework reference]
10. Shay JW, Wright WE. Telomeres and telomerase in normal and cancer stem cells. FEBS Letters. 2010;584(17):3819-3825. doi:10.1016/j.febslet.2010.05.010 [Telomerase and cancer risk context]